The Royal Marsden NHS Foundation Trust, Chelsea Research Centre
Welcome,         Profile    Billing    Logout  
 7 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Khoo, Vincent
NCT03850795: HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Terminated
3
104
Europe, Canada, US, RoW
HC-1119, Enzalutamide
Hinova Pharmaceuticals USA, Inc.
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
06/24
06/24
PEACE III, NCT02194842 / 2014-001787-36: Phase III Radium 223 mCRPC-

Active, not recruiting
3
446
Europe, Canada, RoW
Ra223, Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC, Bayer, Astellas Pharma Europe Ltd., UNICANCER, Canadian Urologic Oncology Group, Latin American Cooperative Oncology Group, Cancer Trials Ireland
Prostate Cancer
02/24
12/28
DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting
3
1100
Europe, Canada, US, RoW
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/28
07/28
NCT02759783: Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases

Active, not recruiting
2/3
245
Europe, RoW
SBRT, Stereotactic body Radiotherapy, SABR, Standard of Care
Royal Marsden NHS Foundation Trust, Institute of Cancer Research, United Kingdom, National Health Service, United Kingdom
Prostate Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung
10/24
10/24
SOGUG-NEOWIN, NCT06511648 / 2022-002586-15: Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Recruiting
2
90
Europe
Erdafitinib monotherapy, Cetrelimab and Erdafitinib combination
Spanish Oncology Genito-Urinary Group, Janssen-Cilag Ltd., Pivotal S.L.
Muscle-invasive Bladder Cancer
03/26
03/29
IP2-ATLANTA, NCT03763253: Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms

Recruiting
2
399
Europe
Standard of Care, Minimally Invasive Ablative Therapy (MIAT), Metastatic Directed Therapy (MDT), Radical Therapy (Prostatectomy or Radiotherapy)
Imperial College London, Wellcome Trust
Prostate Cancer, Metastatic Prostate Cancer
08/26
01/27
DURANCE, NCT04106115: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Recruiting
1/2
64
Europe
Durvalumab, MEDI 4736, S-488210/S-488211, S-488210/Montanide, S-488211/Montanide
University College, London, AstraZeneca, Shionogi
Bladder Cancer
05/25
05/29
IP4-CHRONOS, NCT04049747: Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer

Recruiting
N/A
2450
Europe
Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy], radiotherapy, prostatectomy, external beam radiotherapy, brachytherapy, Focal therapy, high intensity focused ultrasound, cryotherapy, HIFU, Focal therapy after Finasteride 5Mg tablets for 12 weeks, Neoadjuvant, Focal therapy after Bicalutamide 50Mg tablets for 12 weeks
Imperial College London, Prostate Cancer UK, Imperial Clinical Trials Unit (ICTU)
Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Adenocarcinoma
10/21
05/27
IP5-MATTER, NCT04590976: Metastatic Prostate Cancer Men's Attitudes Towards Treatment of the Local Tumour and Metastasis Evaluative Research

Completed
N/A
320
Europe
Semi-Structured Interview Healthcare Professional, Semi-Structured Interview Patients, Think Aloud Interview Patients, Discrete Choice Experiment (DCE) Patients
Imperial College London, University of Aberdeen
Prostate Cancer Metastatic, Radiotherapy Side Effect, Surgery, Urologic Cancer, Quality of Life, Patient Satisfaction, Health Care Utilization
02/23
02/23
SABRE, NCT04905069: Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy

Recruiting
N/A
500
Europe, US, RoW
SpaceOAR Vue System
Boston Scientific Corporation
Prostate Cancer
04/27
04/30
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32

Download Options